Drug Safety Archives

Blog

How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most

Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…

CertaraJanuary 26, 2026

Webinar

Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

CertaraJanuary 22, 2026

Webinar

CHI ADC Webinar: Start Right-Finish Strong: Antibody-Drug Conjugate (ADC) Studies For Success

Danielle PillsburyJanuary 14, 2026

Webinar

Safety First: Uncovering the Clinical Risks Inside Your Compound Screening Data

CertaraJanuary 13, 2026

Fact Sheet

Add Off-target Risk Profiling to Your Analyses

Certara's cheminformatics solution, D360, supports a key feature of Secondary Intelligence: a low-medium-high ranking of…

CertaraJanuary 5, 2026

Publication

A Systematic Review and Model-Based Meta-Analysis of Pegylated-Interferon-α-Induced HBsAg Loss in Chronic Hepatitis B Virus Infection

This study synthesizes data from a large body of clinical trials to evaluate rates of…

CertaraDecember 18, 2025

Case Study

Merck Advances Pediatric Oncology with Innovative ADC Modeling

Merck leveraged ADC modeling and pediatric ADC dose optimization to enable FDA acceptance and advance…

CertaraDecember 12, 2025

Case Study

Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling

Discover how Certara applied exposure-response analysis and advanced modeling to optimize Donidalorsen dosing for hereditary…

CertaraNovember 10, 2025

On-Demand Webinar

In silico Safety and Toxicology assessment: ToxStudio®

Discover how Certara’s ToxStudio align with FDA’s roadmap to reduce animal testing and transform preclinical…

CertaraOctober 30, 2025

On-Demand Webinar

AAPS Webinar – Pediatric Drug Development: Why It’s Critical to Submission Strategy and How Modeling, Regulatory, and Clinical Insights Shape Success

Learn how model-informed drug development, clinical pharmacology, and regulatory strategy support successful pediatric drug development…

CertaraOctober 21, 2025

Drug Safety

How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most

Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

CHI ADC Webinar: Start Right-Finish Strong: Antibody-Drug Conjugate (ADC) Studies For Success

Safety First: Uncovering the Clinical Risks Inside Your Compound Screening Data

Add Off-target Risk Profiling to Your Analyses

A Systematic Review and Model-Based Meta-Analysis of Pegylated-Interferon-α-Induced HBsAg Loss in Chronic Hepatitis B Virus Infection

Merck Advances Pediatric Oncology with Innovative ADC Modeling

Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling

In silico Safety and Toxicology assessment: ToxStudio®

AAPS Webinar – Pediatric Drug Development: Why It’s Critical to Submission Strategy and How Modeling, Regulatory, and Clinical Insights Shape Success

Newsletter sign up

Quick links

Solutions

Contact